SCHEMBL392858

SCHEMBL392858

O=C(O)CCC(=O)c1ccc(Cl)cc1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.65
KMT2A Q03164 3/20 0.64
USP5 P45974 1/20 0.63
RAB9A P51151 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
FFAR1 O14842 1/20 0.62
LMNA P02545 1/20 0.62
CYP1A2 P05177 1/20 0.62
HIF1A Q16665 1/20 0.62
GSK3B P49841 2/20 0.59
ALDH1A1 P00352 1/20 0.59
GAA P10253 1/20 0.59
CYP2C19 P33261 1/20 0.59
L3MBTL1 Q9Y468 3/20 0.57
MEN1 O00255 2/20 0.57
MAPT P10636 2/20 0.57
HPGD P15428 1/20 0.57
ERCC5 P28715 1/20 0.57
FEN1 P39748 1/20 0.57
NPC1 O15118 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7857464 0.94 SMN1; SMN2 (0.72) NR4A2KMT2AUSP5RAB9ASMN1; SMN2
SCHEMBL16552727 0.91 GSK3B (0.70) KMT2ARAB9ASMN1; SMN2LMNAGSK3B
SCHEMBL10865120 0.89 MMP1 (0.69) NR4A2KMT2AUSP5RAB9ASMN1; SMN2
SCHEMBL4902972 0.89 L3MBTL1 (0.59) NR4A2KMT2AUSP5RAB9ASMN1; SMN2
SCHEMBL10353454 0.89 NR4A2 (0.81) NR4A2KMT2AUSP5RAB9ASMN1; SMN2
SCHEMBL2743322 0.88 PDE4B (0.61) NR4A2KMT2AUSP5RAB9ALMNA
SCHEMBL5849297 0.88 HDAC3 (0.66) NR4A2KMT2AUSP5RAB9ALMNA
SCHEMBL28372673 0.87 L3MBTL1 (0.72) NR4A2KMT2ARAB9ASMN1; SMN2FFAR1
SCHEMBL6931350 0.86 TP53 (0.60) NR4A2KMT2AUSP5RAB9ASMN1; SMN2
SCHEMBL6156591 0.86 HDAC3 (0.69) KMT2AUSP5LMNAGSK3BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
CN-113214195-B Method for asymmetrically synthesizing dihydrofuran 2- (3H) -ketone compound by nickel catalysis 云南民族大学 2024-05-10 CN claimed
US-11884628-B2 Method for synthesizing lactam derivatives without use of catalyst GUIZHOU UNIVERSITY (CN) 2024-01-30 US claimed
US-20220177429-A1 METHOD FOR SYNTHESIZING LACTAM DERIVATIVES WITHOUT USE OF CATALYST GUIZHOU UNIVERSITY (CN) 2022-06-09 US claimed
CN-113214195-A Method for asymmetrically synthesizing dihydrofuran 2- (3H) -ketone compound by nickel catalysis 云南民族大学 2021-08-06 CN claimed
WO-2020228170-A1 CATALYST-FREE SYNTHESIS METHOD FOR LACTAM DERIVATIVE 贵州大学 2020-11-19 WO claimed
CN-109942473-B Method for synthesizing lactam derivative without catalyst 贵州大学 2020-09-15 CN claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 US claimed
US-7691889-B2 Antimycobacterial compounds LUPIN LIMITED (IN) 2010-04-06 US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050192275-A1 Novel antimycobacterial compounds LUPIN LIMITED (IN) 2005-09-01 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
EP-0912467-B1 ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE RHODIA CHIMIE SA (FR) 2002-04-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS NR4A2 3703/4885KMT2A 2681/4885USP5 759/4885
US-11884628-B2 Method for synthesizing lactam derivatives without use of catalyst COASY, SI, NAAA NR4A2 4625/4885KMT2A 321/4885USP5 1016/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS NR4A2 3703/4885KMT2A 2681/4885USP5 759/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 NR4A2 801/4885KMT2A 1624/4885USP5 4421/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 NR4A2 2413/4885KMT2A 826/4885USP5 824/4885
US-20220177429-A1 METHOD FOR SYNTHESIZING LACTAM DERIVATIVES WITHOUT USE OF CATALYST COASY, SI, NAAA NR4A2 4625/4885KMT2A 321/4885USP5 1016/4885
US-20050192275-A1 Novel antimycobacterial compounds MDH1, IMMT, MLYCD NR4A2 4005/4885KMT2A 3434/4885USP5 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.